K. Flanigan
Nationwide Children's Hospital(US)The Ohio State University(US)
Publications by Year
Research Areas
Muscle Physiology and Disorders, Neurogenetic and Muscular Disorders Research, RNA Research and Splicing, Cerebral Palsy and Movement Disorders, RNA modifications and cancer
Most-Cited Works
- → The Art of the Possible …(1982)12 cited
- → Motor and Cognitive Assessment of Infants and Young Boys with Duchenne Muscular Dystrophy; Results from the Muscular Dystrophy Association DMD Clinical Research Center Network (P04.084)(2012)3 cited
- → PP09.16 – 2691: Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne muscular dystrophy (DMD): 3.2 year update on six-minute walk test (6MWT), pulmonary function testing (PFT), and safety(2015)2 cited
- → Moderate Walking Distances and Velocity Correlate with Function Comparable to 6 Minute Walk Test (S49.005)(2012)2 cited
- → The TREAT-NMD Advisory Committee for Therapeutics (TACT): An innovative de-risking model to foster orphan drug development(2015)2 cited
- → DUCHENNE MUSCULAR DYSTROPHY - PHYSIOTHERAPY(2018)1 cited
- → The 100-meter timed test: ability to detect change over time in Duchenne muscular dystrophy(2017)1 cited
- → TREAT-NMD (translational research in Europe, assessment and treatment for neuromuscular disorders)(2015)1 cited
- → P.11.20 Results at 2 years of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with DMD(2013)1 cited
- → Ataluren: Clinical Trial Results in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)(2016)1 cited